Encephalitis Clinical Trial
Official title:
EURopean Study on Encephalitis in Intensive CAre
Prospective observational multicenter study in European ICUs. All patients admitted to the ICU for probable or confirmed Acute encephalitis (2013 IDSA - Infectious Disease Society of America criteria) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.
Primary objective : evaluate the correlation between mRs score and the baseline characteristics Functional outcomes will be evaluated using the modified Rankin score (mRS) score, which is one of the most frequently used scores in acute neurological diseases [18]. A poor outcome will be defined by a mRS score > 2 (functional dependence or death). The investigator usually evaluates this score if the patient is still in the hospital 90 days after admission. Patients discharged from hospital within 90 days following ICU admission without major disability (mRS 0, 1 or 2) are considered to have a good outcome. Patients discharged within 90 days with a disability will be classified for the study according to the latest available data. Patients will not be contacted directly by the investigator for the study purposes. Secondary objectives : To identify additional prognosis factors : the clinical, radiological, biological and neurophysiological factors associated with poor outcome for patients admitted to the ICU with AE - Day 28 mortality, in-ICU mortality, in-hospital mortality - Major systemic complications (septic shock, hyponatremia, nosocomial pneumonia, catheter-related BSI, overt gastroenteral bleeding, pulmonary embolism) - Major intracranial complications during ICU stay - Status epilepticus - Brain death - Empyema/cerebral abscess - Cerebral ischemia - Intracranial bleeding - ICP monitoring - Neurosurgery The cause of death will be categorized into 2 categories: - Systemic causes (cardiovascular failure, MOF) - Neurological cause (Diffuse neurologic injury or withdrawal of care) ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538094 -
tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis
|
N/A | |
Completed |
NCT00381433 -
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
|
Phase 1 | |
Completed |
NCT00031486 -
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
|
Phase 3 | |
Completed |
NCT00069303 -
Natural History of West Nile Virus Infection
|
N/A | |
Completed |
NCT02906631 -
Epidemiology and Prognosis of Encephalitis in Intensive Care
|
||
Completed |
NCT02367664 -
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
|
Phase 3 | |
Completed |
NCT00314132 -
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
|
Phase 3 | |
Terminated |
NCT00927953 -
Treatment of West Nile Virus With MGAWN1
|
Phase 2 | |
Recruiting |
NCT05393492 -
Regulating Emotions and Behaviors After Brain Injury
|
N/A | |
Terminated |
NCT04361344 -
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection
|
N/A | |
Recruiting |
NCT04460599 -
Neurological Features During COVID19
|
||
Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
Completed |
NCT02714959 -
IL-2 in Refractory Autoimmune Encephalitis
|
Phase 1/Phase 2 | |
Completed |
NCT01092507 -
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
|
Phase 3 | |
Completed |
NCT01041573 -
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
|
Phase 3 | |
Not yet recruiting |
NCT04722328 -
Establishment of Prevention and Control System of Central Nervous System Infection
|
||
Recruiting |
NCT06067750 -
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
|
||
Not yet recruiting |
NCT06368648 -
CoMind Early Feasibility Study
|
||
Completed |
NCT02526550 -
Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
|
Phase 4 | |
Completed |
NCT01694524 -
Nervous System Infections Among Patients With Febrile Seizure
|
N/A |